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Abstract Adjuvant treatment of patients with endometrial
cancer is tailored to clinical-pathological prognostic factors.
Pelvic radiation therapy for stage I endometrial cancer (EC)
provides a highly significant improvement of local control,
but without survival advantage. Low-risk EC patients have
a very favorable prognosis, and should be observed after
surgery. Use of adjuvant radiotherapy (RT) is limited to
patients with high-intermediate or high-risk factors. For
those with high-intermediate risk features, vaginal brachy-
therapy alone provides excellent vaginal control with less
morbidity and better quality of life than pelvic external
beam RT (EBRT). For patients with stage I–III EC with
high-risk features, the use of adjuvant chemotherapy alone
has not shown survival benefit as compared to pelvic EBRT.
A first trial comparing pelvic EBRT with or without
adjuvant chemotherapy has shown better progression-free
survival with combined therapy. Current ongoing trials are
exploring the role of combined RT and chemotherapy,
compared to chemotherapy or RTalone.
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Quality of life
Introduction
Endometrial cancer (EC) is the most common gyneco-
logical cancer and primarily affects postmenopausal
women between 60 and 85 years of age. Many patients
have concurrent comorbidities, such as obesity, diabetes,
and cardiovascular diseases. Annual incidence rates in
European countries range between 15 and 20 per
100,000 women; incidence in the United States is 23
per 10
5 women per year [1, 2].
The large majority of patients are diagnosed at early
stage (International Federation of Gynecology and Obstet-
rics [FIGO] stage I), due to early symptoms. Surgery,
consisting of total abdominal hysterectomy and bilateral
salpingo-oophorectomy (TAH-BSO), is the primary treat-
ment. More recently, laparoscopic surgery (laparoscopic-
assisted vaginal hysterectomy or total laparoscopic hyster-
ectomy) has been introduced for early-stage disease. The
advantages of laparoscopy are the shorter hospitalization
and recovery time and decrease of surgical morbidity.
Disadvantages are the increased length of the operation
and the learning curve involved with laparoscopic techni-
ques. First results from randomized trials comparing
laparoscopic surgery to abdominal surgery have shown the
overall (OS) and relapse-free survival (RFS) rates to be
similar to laparotomy [3], with shorter hospital stay, more
rapid recovery, and less pain, while complication rates were
similar [4]. Short-term quality of life (up to 4 weeks post-
surgery), especially physical functional well being, was
better after laparoscopy [5].
The role of pelvic and para-aortic lymphadenectomy or
lymph node sampling has been widely debated. Two large
randomized trials have been published, both showing no
differences in overall or progression-free survival rates
between the arms with and without lymphadenectomy (LA)
for patients with stage I EC. Although LA did identify 13%
microscopic nodal metastases in the LA group, as com-
pared to 3% in the no-LA group, survival and patterns of
relapse were identical in the two groups [6, 7].
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based on surgical and pathology findings. In 2009, the
revised FIGO staging system was published, which
replaced the 1988 FIGO staging system [8]. Especially the
changes in stage IA, IB, and IC should be kept in mind
when evaluating literature data, as FIGO 1988 stage IA and
IB have been grouped together in FIGO 2009 as stage IA,
and FIGO 1988 stage IC is IB in FIGO 2009 [8].
Risk Groups and Adjuvant Radiation Therapy
Major prognostic factors for endometrial carcinoma are
stage, age, histological type, grade, depth of myometrial
invasion, and presence of lymph-vascular space invasion
(LVSI). Adjuvant radiotherapy (RT) for endometrial
carcinoma has increasingly been tailored to these risk
factors. Based on staging studies and prospective and
retrospective data, endometrial carcinoma has been
classified as low-risk, intermediate-risk, and high-risk
for lymph node metastases and/or early disease spread to
the abdominal cavity and to distant sites. The majority of
patients with EC have low to intermediate (55%) or
high-intermediate (30%) risk features; only 15% have a
high-risk profile. FIGO staging was updated in 2009; risk
profiles have been based on the 1988 FIGO stage but have
been updated to FIGO 2009 criteria. Low-risk are FIGO
2009 [8] stage IA (with no or superficial [<50%] myometrial
invasion) EC, grade 1 or 2, of endometrioid type histology.
High-risk are FIGO stage IB (ie, outer [>50%] myometrial
invasion) of grade 3 or of non-endometrioid histology; or
stage II or III EC. All other stage I EC are intermediate risk;
this group has further been refined with other factors to define
a high-intermediate risk (HIR) group [9, 10]. Five-year
survival rates for patients with intermediate-risk EC are 80–
85%, with most of these patients dying of intercurrent
diseases; rates of endometrial cancer death are 8–10%.
For low-risk EC standard treatment is surgery alone,
with 95% probability of 5-year RFS. For intermediate-
risk EC, four large randomized trials have established the
role of adjuvant external beam pelvic radiotherapy
(EBRT; Table 1)[ 9–11, 12￿￿]. The Norwegian trial,
published in 1980, included 540 women with clinical
stage 1 endometrial carcinoma [11]. After hysterectomy
and postoperative vaginal brachytherapy (60 Gy to the
mucosal surface), patients were randomly assigned to
a d d i t i o n a lE B R T( 4 0G yi n2G yf r a c t i o n s )o ro b s e r v a t i o n .
Although additional EBRT reduced vaginal and pelvic
relapse rates (2% at 5 years vs 7% in the control group),
more distant metastases were found in the RT group (10%
vs 5%), and survival was not improved (89% vs 91% at
5 years). The subgroup with grade 3 tumors with deep
(>50%) myometrial invasion showed improved local
control and survival after EBRT (18% vs 27% cancer-
related deaths); however, there were too few patients in
this category to reach significance.
In the first Post-Operative Radiation Therapy in Endo-
metrial Carcinoma (PORTEC) trial, 715 patients with stage
I endometrial carcinoma, grade 1 or 2 with deep (≥50%)
myometrial invasion or grade 2 or 3 with superficial
(<50%) invasion, were randomized after TAH-BSO to
receive EBRT (46 Gy in 2 Gy fractions) or no additional
treatment (NA T) [9]. The 10-year locoregional relapse rates
were 5% in the EBRT group and 14% in the control group
(P<0.0001). There was no significant survival difference
between the treatment arms, with 10-year overall survival
of 68% (EBRT) vs 73% (NA T, P=0.14) and endometrial
cancer–related death rates of 10% and 8% (P=0.47) [13].
Risk criteria for locoregional relapse were grade 3, age
older than 60 years, and outer 50% invasion.
Table 1 Randomized trials of adjuvant radiation therapy in stage I endometrial carcinoma
Trial (ref) accrual period No. patients eligibility Surgery Randomization Locoregional
recurrence
Survival
Norwegian [11]
1968–1974
540 Stage I TAH-BSO VBT vs VBT +
pelvic RT
7% vs 2% at 5 years
P<0.01
89% vs 91% at
5 years P=NS
PORTEC-1 [9]
1990–1997
714 IB grade 2–3I C
grade 1–2
TAH-BSO NA T vs pelvic RT 14% vs 4% at 5 years
P<0.001
85% vs 81% at
5 years P=0.31
GOG-99 [10]
1987–1995
392 Stage IB, IC
Stage II (occult)
TAH-BSO and
lymphadenectomy
NA T vs pelvic RT 12% vs 3% at 2 years
P<0.01
86% vs 92% at
4 years P=0.56
ASTEC/EN5 [12￿￿]
1996–2005
905 Stage IAB g3, IC,
Stage II, serous/cc
TAH-BSO ±
lymphadenectomy
NA T vs pelvic RT 7%
a vs 4% at 5 years
P=0.038
84% vs 84% at
5 years P=0.98
PORTEC-2 [21￿￿]
2002–2006
427, age >60 IB grade 3
IC grade 1–2
TAH-BSO VBT vs pelvic RT 2% vs 2% at 5 years
P=0.74
85% vs 80% at
5 years P=0.57
a53% in NA Tarm received VBT; isolated locoregional recurrence reported
NAT no additional treatment; RT radiation therapy; VBT vaginal brachytherapy
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group and 48% in the control group (P<0.001) [14]. This
was due to the fact that 75% of locoregional relapses in the
NA T group were located in the vagina. After vaginal
relapse, 5-year actuarial survival was 64%; 38% in the
EBRT group versus 70% in the NA T group, which shows
the high salvage rates of vaginal relapse in patients not
previously irradiated. In contrast, outcome after pelvic and
distant relapse was poor, with only 11% 5-year survival.
The GOG#99 trial included 392 evaluable patients with
FIGO 1988 stage IB, IC, or IIA endometrial carcinoma of
any histological grade, who were randomized after TAH-
BSO and lymphadenectomy to receive pelvic EBRT
(50.4 Gy in 1.8 Gy fractions) or NA T [10]. A high-
intermediate risk group (HIR, 33% of the study patients)
was defined based on the prognostic factors age, histolog-
ical grade, myometrial invasion, and the presence of
lymphovascular space invasion. RT resulted in similar
hazard reductions for the HIR and LIR subgroups (58%
and 54%), but in absolute terms, the differences were
greater for HIR patients, with a reduction of 4-year
cumulative relapse from 27% (NA T) to 13% (RT). The 2-
year estimated vaginal and pelvic failure rate was 12% in
the NA T group and 3% in the EBRT group, for a 58%
hazard reduction by RT. These results are strikingly similar
to those obtained in the PORTEC study without lymphade-
nectomy. However, the 4-year crude rate of severe
complications in GOG-99 was 13%, which underlines the
increased risk of toxicity when combining extended surgery
with pelvic radiotherapy. In addition, GOG#99 has shown
that the HIR factors are associated with increased risk of
relapse, regardless of lymphadenectomy, and that LVSI is
strongly associated with risk of lymph node involvement,
as well as risk of relapse at distant sites and inferior
outcome in absence of lymph node metastases [10, 15, 16].
In the pooled ASTEC and EN5 trials, 905 patients with
stageIendometrialcarcinomawithriskfeatures(deepinvasion
or high grade) were randomly allocated to EBRT or NA T
[12￿￿]. There was no difference in overall survival (84% at
5 years in both groups), confirming the results of the
PORTEC and GOG#99 trials. In the ASTEC/EN5 trial,
brachytherapy was used at discretion of the centers and was
used in both arms. As a consequence, 51% of the patients in
the NA Tarm received vaginal brachytherapy. This can explain
the fact that the 5-year rate of isolated (not total) vaginal or
pelvic recurrence was 6.1% in the NA T arm, compared to
3.2% in the EBRTarm (hazard ratio 0.46, P=−0.02).
Conclusions from these randomized trials are that EBRT
provides a highly significant improvement of local control,
but without survival advantage. Furthermore, mild adverse
effects were recorded in 26% of EBRT patients in the
PORTEC-1 trial, predominantly gastrointestinal (GI) toxic-
ity [17]. A large proportion of endometrial cancer patients
has a very favorable prognosis, and should be observed
after TAH-BSO. Radiation therapy is a very effective
salvage treatment for vaginal relapse in patients not
previously irradiated. The use of postoperative RT should
therefore be limited to the group of patients at sufficiently
high risk of locoregional relapse to warrant the risk of
treatment-associated morbidity. The 10-year locoregional
relapse rates in the PORTEC-HIR group were 4.6% in the
RT group and 23.1% in the control group [13]. In the GOG-
99 trial, EBRT provided a reduction of isolated 4-year local
relapse in the HIR group from 13% to 5%.
Adjuvant Vaginal Brachytherapy Alone
The results of the randomized trials for intermediate-risk
endometrial carcinoma suggested that, in view of the
absence of survival benefit with EBRT and of the fact that
most (75%) locoregional recurrences were located in the
vagina, vaginal brachytherapy (VBT) might also be
effective for patients with high-intermediate risk features
to obtain local control with fewer side effects than EBRT
and better quality of life. Data from retrospective studies
that used VBT alone for stage I, mainly low-risk EC
showed 5-year rates of vaginal relapse of 0–5% [18–20].
This was the rationale for the randomized PORTEC-2 trial,
which compared EBRT and VBT with regard to efficacy,
side effects, and health-related quality of life (HRQL). In
the PORTEC-2 trial, 427 patients with FIGO 1988 stage I–
IIA endometrial carcinoma with high-intermediate risk
features (age of at least 60 years, grade 1 or 2 tumors with
outer 50% invasion or grade 3 with inner 50% invasion)
were randomly assigned after surgery (TAH-BSO) to EBRT
(n=214) or VBT (n=213). Final results of the PORTEC-2
trial showed vaginal brachytherapy to be highly effective in
preventing vaginal relapse. At median follow-up of
45 months, estimated 5-year rates of vaginal recurrence
were 1.8% for VBT and 1.6% for EBRT (P=0.74). Five-
year rates of locoregional relapse (VR and/or PR) were
5.1% and 2.1% (P=0.17). Only 1.5% versus 0.5% (P=0.30)
presented with isolated pelvic recurrence (PR); other PR
were part of widespread disease relapse. Rates of DM were
similar (8.3% vs 5.7%, P=0.46). There were no differences
in OS (84.8% vs 79.6%, P=0.57) and DFS (82.7% vs
78.1%, P=0.74) between the groups. Rates of grade 1–2
gastrointestinal toxicity were significantly lower in the
VBT group [21￿￿]. Quality of life was significantly better in
the VBT arm. Patients who had brachytherapy reported
better social functioning (P<0.002) and lower symptom
scores for diarrhea, fecal leakage, the need to stay close to
the toilet, and limitation in daily activities due to bowel
symptoms (P<0.001). Sexual functioning and symptoms
did not differ between the treatment arms [22￿]. In view of
474 Curr Oncol Rep (2011) 13:472–478the efficacy of VBTwith fewer side effects and better quality
of life, VBTalone has in many countries become standard of
care for patients with EC with high-intermediate risk features.
Adjuvant Chemotherapy for High-Risk
and Advanced-Stage EC
Patients with high-risk endometrial cancer (FIGO 2009 stage
IB grade 3, stages II–III, and those with serous or clear cell
cancers with myometrial invasion) have an increased risk of
distant metastases and endometrial cancer death, and the role of
adjuvant chemotherapy has been investigated in several trials
(Table 2). Three randomized trials have investigated use of
adjuvant chemotherapy as compared to radiation therapy [23–
25]. Both the Japanese and Italian trials used cyclophospha-
mide, doxorubicin, and cisplatin (CAP) chemotherapy (3 or 5
cycles, respectively), randomly compared to pelvic EBRT
alone. In the Japanese trial (385 patients) [23], no differences
in overall survival, relapse rate, or progression-free survival
were found. Grade 3–4 toxicity was reported in 4.7% (CAP)
versus 1.6% (EBRT) of the patients. The Italian trial (345
patients) included 65% patients with stage III EC, reflected in
5-year overall survival of 69% vs 66% (P=0.77) [24]. There
were no differences in 5-year OS, PFS, or RR. More grade 3
toxicity was reported in the CAP arm (39% hematologic, 10%
nausea/vomiting) than in the EBRT arm (16%, mainly GI
toxicity). In the GOG#122 trial, 396 patients with advanced
disease (stage III and IV EC) were included [25]. This trial
a l l o w e dr e s i d u a lm a c r o s c o p i cd i s e a s eu pt o2c m ,a n du s e d
prolonged chemotherapy, 8 cycles of doxorubicin and
cisplatin (AP) in one arm; and whole-abdominal radiation
therapy (W ART) in the second arm. Predicted 5-year survival,
adjusted for stage, was significantly better for AP (55% vs
42%), both for the whole study population and for the 73%
stage III patients, but toxicity was substantial: grade 3–4G I
toxicity 20% versus 13%, and neurologic toxicity 7% versus
1%; 17% of patients did not complete AP in view of toxicity.
Event rates were similar (54% vs 50%), and unadjusted
predicted 5-year PFS rates were 42% versus 38%. W ART
cannot be recommended for treatment of abdominal disease
spread.
Role of Combined Radiation Therapy
and Chemotherapy
The trials comparing adjuvant chemotherapy (CT) alone
and adjuvant EBRTalone showed that while chemotherapy
delayed distant relapse, pelvic EBRT delayed pelvic relapse
and the overall and relapse-free survival rates were similar.
PelvicEBRTisstillregardedanessentialtreatmentcomponent
Table 2 Randomized trials investigating adjuvant chemotherapy and/or radiotherapy in endometrial cancer
Trial (ref) No. patients eligibility/stage Randomization Pelvic recurrence Overall survival
Susumu et al. [23] 385 Stage I–III with >50%
MI (60% stage IB)
Pelvic RT vs chemotherapy
(3× CAP)
7% vs 7% P=ns 85% vs 87% P=ns
Maggi et al. [24]3 4 5 I B –II grade 3 (35%) III (65%) Pelvic RT vs chemotherapy
(5× CAP)
12% vs 16% P=ns 69% vs 66% P=ns
Randall et al. [25] 396 III; IV (28%) (residual <2 cm) W ART vs chemotherapy
(8× AP)
13% vs 18% 42% vs 53% P<0.01
Morrow et al. [28] 181 Clinical stage I II (occult)
31% node+
Pelvic RT vs pelvic RTand
chemotherapy (6–8× A)
N/A No difference P=ns
Kuoppala et al. [29] 156 Stage IA g3, IB,
Stage II–IIIA (46% stage IB)
Pelvic RT vs pelvic RTand
chemotherapy (3× CEP)
3% vs 2% P=ns 85% vs 82% DSS
5 years P=ns
Hogberg et al. [30￿￿] 382 Stage I–III Stage I
serous (49% stage IB)
Pelvic RT vs pelvic RTand
chemotherapy
(4× AP/TAP/TC/TEP)
N/A 76% vs 83% P=ns
Ongoing trials Planned no. Randomization Accrual January 2011
PORTEC-3 670 Stages I–III with
high-risk factors; serous/cc
Pelvic RT vs RT-CT
(2× C during RTand 4× TC)
300
GOG#249 562 Stages I–II with
high-risk factors or serous/cc
Pelvic RT vs VBTand
CT (3× TC)
175
GOG#258 804 Stages III/IV RT-CT (2× C during RTand 4× TC)
vs CT (6× TC)
132
A doxorubicin; AP doxorubicin/cisplatin; CAP cyclophosphamide/doxorubicin/cisplatin; CEP cyclophosphamide/epirubicin/cisplatin; CT
chemotherapy; ns not statistically significant; RT radiation therapy; TAP paclitaxel/doxorubicin/cisplatin; TC paclitaxel/carboplatin; TEP
paclitaxel/epirubicin/cisplatin; WARTwhole abdominal radiotherapy
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tive studies reported significantly higher rates of pelvic
recurrence if high-risk patients were treated without RT [26,
27]. In a retrospective analysis of 43 patients with high-risk
or advanced-stage endometrial carcinoma who received
chemotherapy alone, 67% relapsed, of whom 40% had
pelvic recurrence and 56% distant relapse. The 3-year pelvic
failure rate was 47%, and in 31% the pelvis was the first or
only site of recurrence [26]. Inananalysisof71stageIIICEC
patients, those treated with regional RT had a significantly
better 5-year pelvic-relapse-free survival than patients who
received CTalone (98% vs 61%, P=0.001), as well as better
disease-specific survival (78% vs 39%, P=0.01), and overall
survival (73% vs 40%, P=0.03). In patients treated without
regional RT, the most common site of relapse was the pelvis
[27].
The way forward might be to combine CT and RT. This
has first been investigated in a small GOG trial (181
patients, closed early and flawed by many patients not
receiving chemotherapy) in which patients were assigned to
RT with or without single-agent doxorubicin. This trial did
not show any difference in survival or recurrence patterns
[28]. A Finnish trial was also underpowered, with 156
patients randomized to EBRT with or without 3 cycles of
cisplatin, epirubicin, and cyclophosphamide (CEP); mainly
intermediate-risk patients. This trial showed no differences
in the rates of survival (P=0.77) or recurrence (RT vs RT +
CT: 18% vs 22%), but more toxicity in the RT+CT arm
(severe bowel toxicity 9.5% vs 2.8%) [29].
The most recent and largest trial, NSGO 9501/EORTC
55991, randomly compared EBRT with or without four
cycles of CT in 382 patients. V arious chemotherapy
combinations were used, mainly doxorubicin and cisplatin
(AP), but also AP with paclitaxel (TAP), cisplatin or
carboplatin with paclitaxel (TP or TC), and TP with
epirubicin (TEP), given before or after RT. This trial was
the first to show a significant 7% increase in progression-
free survival with the addition of chemotherapy (79% vs
72%, P=0.03), but no significant difference in overall
survival. In the published pooled data analysis with the
Italian MaNGO ILIADE-III trial (157 patients, for a
combined total of 534 evaluable patients), results were
similar, with a statistically significant difference in 5-year
PFS favoring the combined arm (78% vs 69%, P=0.009),
but only a trend for improved 5-year OS (82% vs 75%, P=
0.07) [30]. It should be noted that although NSGO/EORTC
and GOG122 trials both showed PFS benefit with chemo-
therapy for the overall trial populations, neither showed a
trend for PFS or OS benefit from adjuvant chemotherapy
for the subpopulations of patients with serous and clear cell
tumors, although these were few in number (20%, n=140 in
NSGO/EORTC and n=100 in GOG#122). The hazard
ratios for PFS and OS with chemotherapy were 0.91 and
1.02 for patients with serous cancer in GOG#122, and 0.83
and 0.94, respectively, for patients with serous cancer in the
NSGO/EORTC trial [25, 30￿￿]. This underlines the need to
establish the efficacy of adjuvant chemotherapy for serous
cancers in randomized trials.
Current Randomized Trials
Anumberoftrialsarecurrentlyongoingwhichfurtherexplore
the role of concurrent chemoradiation and/or adjuvant
chemotherapy. These trials are aimed at answering a number
ofunresolvedissuesinthe treatment ofpatientswithhigh-risk
EC, such as the role of EBRT or VBT in combination with
chemotherapy; the question if overall survival benefit can be
obtained in these elderly patients without impacting too
strongly on their quality of life; if chemotherapy benefits
patients with serous or clear cell cancers; and if combined
treatment should be given to all patients with high risk factors
or only to those with advanced disease.
The international randomized PORTEC-3 trial for
patients with high-risk and advanced-stage disease com-
pares pelvic EBRTalone with combined RT-CT (concurrent
chemoradiation with two cycles of cisplatin during RT,
followed by four adjuvant cycles of carboplatin and
paclitaxel), to establish if RT-CT improves overall and
failure-free survival rates, and the cost/benefit ratio in terms
of toxicity and quality of life. This trial uses a uniform
treatment schedule starting both treatment modalities early,
includes upfront pathology review to ensure that only true
high-risk patients are included, and quality of life assess-
ments to establish short-term and long-term toxicities and
their impact on the patients’ daily life. With international
intergroup collaboration patient accrual is well underway.
The randomized GOG#249 trial for patients with stage I–II
EC with high-intermediate or high-risk factors compares
pelvic EBRTalone, with vaginal brachytherapy followed by
adjuvant chemotherapy (three cycles of carboplatin and
paclitaxel). The randomized GOG#258 trial includes patients
withstage III–IV A ECand comparesthe sameRT -CTschedule
as used in the PORTEC-3 trial with chemotherapy alone (6
cycles of carboplatin and paclitaxel). These GOG trials are
also accruing well (Table 2).
All of these trials are better powered than their
predecessors, and should help resolve many of the
uncertainties regarding which patients may benefit from
chemotherapy and/or radiotherapy.
Conclusions
Over the past decades, randomized trials have established
the role of adjuvant RT for endometrial cancer. The use of
47 Curr Oncol Rep (2011) 13:472–478 6external beam RT has become limited to EC patients with
high-risk factors, sparing many the toxicities and impact on
long-term quality of life of EBRT. Adjuvant brachytherapy
alone has become the standard of care for patients with
high-intermediate risk factors. Randomized trials compar-
ing EBRT and chemotherapy for high-risk EC have not
shown overall survival improvement with chemotherapy
alone; the first trial comparing combined RT and CT has
shown improved progression-free survival compared to RT
alone. Current trials are exploring the roles of concurrent
chemoradiation and/or adjuvant chemotherapy compared to
CT or RT alone. These trials will resolve many of the
uncertainties regarding which patients may benefit from
chemotherapy and/or radiotherapy.
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